近日，临港新片区人才工作领导小组办公室发布了《临港新片区大学生实习基地清单公示 （202411批次）》,标新生物成功入选，将获得管委会的配套实习补贴。
临港新片区大学生实习基地清单公示 （202411批次）
本批实习基地项目是临港新片区人才工作领导小组办公室根据《中国(上海)自由贸易试验区临港新片区大学生实习补贴实施办法》(沪自贸临人才办发〔2024〕7号)相关规定，为促进人才优先发展战略，激发人才创新创造创业活力，对新片区关键核心技术企业给予的特别支持。
此次临港新片区管委会的实习基地政策支持，对标新生物而言是一股强大的推动力，有助于实现企业引才和大学毕业生就业双赢的积极举措，打通校企合作渠道，推动生物医药行业发展。标新生物获批大学生实习基地资格，是临港新片区管委会对公司的企业发展、科研实力、人才培养工作的认可。
标新生物始终坚信“创新驱动发展，人才引领未来”，致力于构建开放、包容、创新的工作学习环境。公司将进一步深化校企合作，探索人才培养新路径。同时，持续拓宽实习岗位、优化实习环境、完善实习管理制度，关注创新创业人才的培养，为大学生提供更广阔的发展空间和平台，促进产学研用深度融合，引领生物医药行业新业态。公司希望以大学生实习基地为契机，与更多高校建立深度合作关系，为更多的大学生提供实践性教育和培养服务，从而共同培养出专业技术人才，为国家的发展贡献力量。
Recently, the Talent Work Leading Group Office of the Lingang New Area released the "Lingang New Area College Student Internship Base List Public Notice (202411)", and Gluetacs has been successfully selected to receive internship subsidies from the management committee.
This batch of internship base projects is a special support given by the Talent Work Leading Group Office of the Lingang New Area to key core technology enterprises in the new area, in accordance with the "China (Shanghai) Pilot Free Trade Zone Lingang New Area College Student Internship Subsidy Implementation Measures", to promote talent priority development strategy and stimulate the innovation, creation, and entrepreneurship vitality of talents.The internship base policy support from the Lin-gang Special Area Administration is a strong driving force for Gluetacs, helping to achieve a win-win situation for enterprise talent attraction and college graduate employment, opening up channels for cooperation between universities and enterprises, and promoting the development of the biopharmaceutical industry. Gluetacs' approval as a college student internship base is a recognition by the Lin-gang Special Area Administration of our company's development, scientific research strength, and talent training efforts.Gluetacs has always believed in "innovation drives development, and talent leads the future", and is committed to building an open, inclusive, and innovative work and learning environment. We will further deepen cooperation with universities and explore new paths for talent training. At the same time, it will continue to expand internship positions, optimize the internship environment, and improve the internship management system, focusing on the cultivation of innovative and entrepreneurial talents, providing college students with broader development opportunities and platforms, promoting deep integration of industry, academia, research, and application, and leading new trends in the biopharmaceutical industry. We hopes to take the college student internship base as an opportunity to establish deep cooperation with more universities, provide practical education and training services for more college students, and jointly cultivate professional technical talents to contribute to the country's development.
标新生物（Gluetacs Therapeutics）是一家专注于研发口服蛋白降解小分子药物的生物医药公司，为上海科技大学孵化的首家生物医药公司，成立于2020年2月，2021年3月正式运营，由多名在蛋白降解领域深耕多年的科学家领衔创立。公司拥有自主知识产权的分子胶降解剂（GLUE）和双机制降解剂（GLUETAC）开发平台，并拥有申请和授权不同国家该领域专利近百项，具备独具特色的差异化技术路线和发展战略。公司现已自主建立人工智能虚拟筛选平台、体外药效筛选平台、药代动力学平台、蛋白质组学平台以及肿瘤动物药效模型平台，实现了完备的全流程药物研发体系建设。标新生物自从2021年3月正式运营以来，成功推动两个候选药物进入临床试验，充分验证和体现了GlueTacs®平台快速发现候选药物和管线推进的能力。标新生物自成立以来受到业内的广泛关注，连续三年获得上海市科技型中小企业称号，荣获2024专精特新中小企业和创新型中小企业称号、2024年度临港新片区科创新锐企业称号、2023上海市高价值专利运营大赛百强、2023中国海归创业大赛三等奖、2023华医榜中国生物医药科技创新价值榜最具成长性小分子创新药企业TOP10、2023临港杯第九届创青春上海青年创新创业大赛一等奖、2022浦东新区全球高校校友科创大赛二等奖，2022中国创新制药企业TOP10、2022第十一届中国创新创业大赛成长组全国赛优秀企业奖、2022第6届医疗健康投资卓悦榜年度生物医药最佳企业、2022第五届中国创翼创业创新大赛上海选拔赛浦东赛区十佳创翼奖、2022浦东新区全球高校校友科创大赛二等奖、2022Venture50新芽榜150强、2021年度全国颠覆性技术创新大赛优秀项目、2021年第二届生物产业年度攀登榜年度最具投资潜质的新锐BioTech、2021中国生物医药产业链创新风云榜金马奖最具关注度新锐企业TOP10奖项。公司陆续获得多项科技部和上海市科委资金支持，纳入临港新片区前沿产业优秀人才安家补贴、重点产业人才补贴、人才引进重点机构名单，知识产权管理体系获得中国专利保护协会认证，多位团队核心成员陆续获得临港新片区十大科技创新先锋人物、谈家桢生命科学产业化奖、杨雄科技创业奖、东方英才创业青年领军人才、上海高层次海外人才和上海市浦江人才等称号。公司也先后成为上海科技大学创新型硕士和工程博士培养单位，并先后与十多位海内外专家教授进行科研研究合作。
About Gluetacs TherapeuticsGluetacs Therapeutics, focusing on the development of oral small molecule protein degrader, is the first biotech company incubated from ShanghaiTech University, Gluetacs was founded in February 2020, and started to operation in March 2021. It was founded by several scientists that have done intensive studies in target protein degradation. The company has independent intellectual property of GLUE degrader and GLUETAC degrader development platform with around 100 patents filed, which has indicated a unique and differentiated technical route and development strategy. The company has established artificial intelligence virtual screening platform, in vitro pharmacodynamics screening platform, pharmacokinetics platform, proteomics platform and in vivo drug pharmacology evaluation platform, and has constructed a complete whole-process drug R&D system. Since its operation in March 2021, Gluetacs Therapeutics has successfully advanced 2 drug candidates into phase I clinical trial, which has demonstrated the GlueTacs® platform's ability to rapidly discover drug candidates and promote pipelines.
